Work

Pembrolizumab-associated myocarditis presenting as symptomatic bradycardia: A case report

Year: 2026

Type: article

Abstract: An 80-year-old woman with Stage IV non-small-cell lung carcinoma developed myocarditis after two doses of pembrolizumab, an immune checkpoint inhibitor. She presented with dizziness and a slow heart rate, diagnosed as junctional rhythm. Echocardiography showed normal heart function, but cardiac MRI revealed subacute myocarditis. After treatment with atropine, a temporary pacemaker, and high-dose prednisone, her condition improved, but junctional rhythm recurred, requiring permanent pacemaker implantation. This case underscores the need for early detection and monitoring of myocarditis in patients receiving ICIs like pembrolizumab.

Source: IHJ Cardiovascular Reports

DOI: 10.1016/j.ihjcvr.2026.05.001

Authors: Billy Joseph David, Mary Jenetrix Co, Richard Henry Tiongco

Institution: St. Luke's Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $400